Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.47 USD | -2.23% | -6.23% | -15.71% |
Financials (USD)
Sales 2024 * | 695M | Sales 2025 * | 760M | Capitalization | 1.36B |
---|---|---|---|---|---|
Net income 2024 * | 58M | Net income 2025 * | 82M | EV / Sales 2024 * | 2.23 x |
Net Debt 2024 * | 196M | Net cash position 2025 * | 49.54M | EV / Sales 2025 * | 1.72 x |
P/E ratio 2024 * |
23.9
x | P/E ratio 2025 * |
15.3
x | Employees | 712 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.74% |
Latest transcript on Pacira BioSciences, Inc.
1 day | -2.23% | ||
1 week | -6.23% | ||
Current month | -6.23% | ||
1 month | +7.28% | ||
3 months | -7.18% | ||
6 months | +1.79% | ||
Current year | -15.71% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Lee
CEO | Chief Executive Officer | 56 | Jan. 01 |
Charles Reinhart
DFI | Director of Finance/CFO | 63 | 11-10-31 |
Jonathan Slonin
CTO | Chief Tech/Sci/R&D Officer | 49 | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Pace
BRD | Director/Board Member | 76 | 08-05-31 |
Paul Hastings
CHM | Chairman | 64 | 11-06-01 |
Andreas Wicki
BRD | Director/Board Member | 64 | 06-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 26 M€ | -4.58% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 28.43 | -2.37% | 53 633 |
24-06-06 | 29.12 | -3.45% | 369,526 |
24-06-05 | 30.16 | -1.18% | 371,786 |
24-06-04 | 30.52 | -1.20% | 880,566 |
24-06-03 | 30.89 | +1.85% | 652,731 |
Delayed Quote Nasdaq, June 07, 2024 at 10:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.71% | 1.36B | |
+45.77% | 754B | |
+40.85% | 630B | |
-5.58% | 352B | |
+20.12% | 331B | |
+9.66% | 298B | |
+18.72% | 250B | |
+12.11% | 217B | |
-0.57% | 216B | |
+6.43% | 164B |
- Stock Market
- Equities
- PCRX Stock